NeuroSense Therapeutics Ltd. (NRSNW)
NASDAQ (CM) NASDAQ (CM) Primary Summary
NeuroSense Therapeutics Ltd. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| BO Brian Oliveira Clear Street Group Inc. | 63,385 | $24,086 | $11,409.3 | -$12,676.7 | -52.63% |
NeuroSense Therapeutics Ltd. (NRSNW) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has NeuroSense Therapeutics Ltd. ever had a stock split?
NeuroSense Therapeutics Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Alon Ben-Noon CEO | NASDAQ (CM) Exchange | M74240116 CUSIP |
| IL Country | 17 Employees | - Last Dividend | - Last Split | 9 Dec 2021 IPO Date |
Overview
NeuroSense Therapeutics Ltd. is a dynamic clinical-stage biotechnology firm dedicated to the advancement of therapies for patients grappling with neurodegenerative diseases across the globe. The inception of the company in 2017 marked the beginning of its journey in the biotechnological industry, centering its operations both in the United States and internationally, with its headquarters nestled in Herzliya, Israel. By focusing on the discovery and development of innovative treatments, NeuroSense Therapeutics aims to bring new hope to individuals living with debilitating conditions such as amyotrophic lateral sclerosis (ALS), Alzheimer's, and Parkinson's disease.
Products and Services
NeuroSense Therapeutics Ltd. has developed a robust portfolio of products and services designed to combat neurodegenerative diseases, which include:
- PrimeC: This leading product stands as an extended-release oral formulation that combines ciprofloxacin and celecoxib in a fixed-dose. PrimeC is primarily under Phase 2b/3 clinical trials for treating amyotrophic lateral sclerosis (ALS). It has also concluded Phase 2 clinical trials for Alzheimer's treatment and is currently undergoing preclinical studies aimed at combating Parkinson's disease.
- StabiliC: Poised at the preclinical stage, StabiliC is being developed with the focus on treating Parkinson's disease. This innovative solution promises to advance the available treatments for Parkinson's, providing new avenues for intervention.
- CogniC: Specifically targeting Alzheimer's disease, CogniC is another significant constituent of NeuroSense's preclinical pipeline. This product represents the company's commitment to addressing the profound challenges faced by those afflicted with Alzheimer's, offering potential for more effective therapies.
